You are here: Industry Insights > Obsidian Therapeutics

News List

Celgene continues dealmaking via agreements with Kyn Therapeutics, Obsidian Therapeutics firstwordpharma
January 21, 2019
Under the first agreement, Celgene will make an upfront cash payment of $80 million to Kyn, whilst also making an equity investment in the company. In return, Celgene will gain exclusive options to globally license Kyn's kynurenine-degrading enzyme and ar
Celgene continues dealmaking via agreements with Kyn Therapeutics, Obsidian Therapeutics firstwordpharma
January 21, 2019
Under the first agreement, Celgene will make an upfront cash payment of $80 million to Kyn, whilst also making an equity investment in the company. In return, Celgene will gain exclusive options to globally license Kyn's kynurenine-degrading enzyme and ar
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies pharmafocusasia
January 21, 2019
Obsidian Therapeutics, a biotechnology company developing cell therapies with pharmacologic operating systems, today announced a strategic collaboration with ....
Obsidian Therapeutics Presents Preclinical Data from Regulated Cytokine Programs that Enable CAR-T Therapies with Controllable Functions biospace
April 18, 2018
Obsidian Therapeutics, Inc. today announced the presentation of preclinical data on its regulated cytokine programs at the Annual Meeting of the American Association for Cancer Research in Chicago, IL.
Cambridge Biotech Obsidian Launches With $49.5M Investment From Google, Takeda, Vertex, Amgen, Ot biospace
December 07, 2017
Obsidian Therapeutics officially launched with the completion of a Series A financing worth $49.5 million.